Key facts
- It has raised $1.9M; the latest was Early Stage VC ($1.9M) in Feb 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Vitalis (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Vitalis (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vitalis (Drug Discovery)
Developer of a non-opioid pharmaceutical therapy intended to manage post-operative pain in total knee arthroplasty patients. The company focuses on creating targeted analgesic drug candidates that reduce or eliminate the need for opioid medications following total knee replacement surgery and offers a unique approach by utilizing its VTS-Aspirin platform, enabling orthopedic surgeons and hospitals with safer, procedure-specific pain-management options.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Employees
- 2
- Website
- vitalispharma.com/
- Ownership
- Privately Held (backing)
Vitalis (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vitalis (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vitalis (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.